Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King, Pain Therapeutics submit abuse-resistant oxycodone NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

King Pharmaceuticals and Pain Therapeutics announce submission of an NDA for their abuse-resistant oral oxycodone formulation Remoxy June 10. The drug, designed to resist common methods of prescription drug misuse and abuse, is indicated for moderate to severe chronic pain. The filing included data from one pivotal trial conducted under a special protocol assessment in over 400 patients with osteoarthritis. There was a statistically significant mean decrease in pain intensity scores between treatment and placebo groups during the 12-week trial

You may also be interested in...



Durect oxycodone drug Remoxy gets priority review

FDA accepts NDA for Pain Therapeutics' Remoxy and grants the pain medication priority review, firms announce Aug. 12. Remoxy, an abuse-resistant oral formulation of oxycodone, is being developed by King Pharmaceuticals and Pain Therapeutics under license from Durect (1Pharmaceutical Approvals Monthly June 2008, p. 40). Remoxy was designed using Durect's Oradur technology, which transforms short-acting capsule dosage forms into sustained release oral products that are less prone to abuse. The NDA was submitted June 10, giving the drug a December user fee date

Supreme Court May Find Patent Board Judges Unconstitutionally Appointed But Favor Narrow Fix

During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.

Pro Beauty Association Opposing Fast-Tracked Bill To Deregulate Licensing In West Virginia

House Bill 2325, on a fast track in West Virginia, would bar the state’s Board of Barbers and Cosmetologists from regulating unlicensed individuals’ use or application of “generally available” cosmetic products for paying clients. PGA’s government affairs team provides detail.

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel